More specifically, patients with a strong intensity of cytoplasmic FGF11 immunoreactivity in their tumours had a significantly worse OS (44%) as compared to those with a weak tumour reactivity (100%) (log rank, p = 0.006, Figure 2C). Here, FGF11 is linked to neoplasm.